基于ceRNA调控原理研究复方鳖甲软肝片对“肝纤维化-肝癌”恶性转化的干预机制

基于ceRNA调控原理研究复方鳖甲软肝片对“肝纤维化—肝癌”恶性转化的干预机制基于ceRNA调控原理研究复方鳖甲软肝片对“肝纤维化-肝癌”恶性转化的干预机制

摘要：

肝纤维化作为肝癌准发病状态之一，是临床难以治愈的肝脏疾病。本研究旨在探讨肝纤维化—肝癌恶性转化过程中，ceRNA网络调控机制的重要性及其干预机制，为治疗肝癌提供新的思路。本研究选取肝纤维化和肝癌相关miRNA和mRNA，构建ceRNA网络，利用生物信息学分析和实验验证，筛选出关键性基因及其通路，为复方鳖甲软肝片的干预提供理论支持。实验结果表明，复方鳖甲软肝片能有效地抑制HSC-T6细胞的增殖和表达FN1、COL1A1等相关基因，打破ceRNA网络的平衡，进而抑制TGF-β1/Smads信号通路、PI3K-Akt信号通路和JAK2-STAT3通路的活性，从而减轻肝纤维化和肝癌的转化程度。综上所述，复方鳖甲软肝片具有良好的治疗肝纤维化—肝癌干预效果，其具体干预机制和临床价值值得更加深入研究。

关键词：ceRNA;肝纤维化;肝癌;复方鳖甲软肝片;干预机制

Abstract:

Liverfibrosis,asapre-cancerousstateoflivercancer,isaclinicallydifficult-to-treatliverdisease.ThepurposeofthisstudyistoexploretheimportanceofceRNAnetworkregulationmechanismintheprocessofliverfibrosis-cancertransformationanditsinterventionmechanism,andtoprovidenewideasforthetreatmentoflivercancer.Inthisstudy,miRNAandmRNArelatedtoliverfibrosisandlivercancerwereselected,andaceRNAnetworkwasconstructed.Thekeygenesandpathwayswerescreenedbybioinformaticsanalysisandexperimentalverification,andtheoreticalsupportwasprovidedfortheinterventionofcompoundBiejiaRuangantablets.TheexperimentalresultsshowedthatCompoundBiejiaRuangantabletscaneffectivelyinhibittheproliferationofHSC-T6cellsandtheexpressionofrelatedgenessuchasFN1andCOL1A1,breakthebalanceofceRNAnetwork,andtherebyinhibittheactivityofTGF-β1/Smadssignalingpathway,PI3K-Aktsignalingpathway,andJAK2-STAT3pathway,resultinginreduceddegreeofliverfibrosisandlivercancertransformation.Insummary,CompoundBiejiaRuangantabletshavegoodtherapeuticeffectsonliverfibrosis-cancerintervention,andtheirspecificinterventionmechanismsandclinicalvalueareworthyoffurtherresearch.

Keywords:ceRNA;liverfibrosis;livercancer;compoundBiejiaRuangantablets;interventionmechanism。Liverfibrosis-cancerisasevereclinicalconditioncharacterizedbytheprogressiveaccumulationofextracellularmatrixproteinsintheliver,leadingtothedevelopmentoflivercancer.Currently,therearefeweffectivetreatmentsforliverfibrosis-cancer,andtheunderlyingmolecularmechanismsarepoorlyunderstood.Inthisstudy,weinvestigatedthetherapeuticeffectsofCompoundBiejiaRuangantabletsonliverfibrosis-cancerinterventionandexploredthespecificinterventionmechanisms.

OurresultsshowedthattreatmentwithCompoundBiejiaRuangantabletssignificantlyreducedthedegreeofliverfibrosisandlivercancertransformationinmice.WefurtherinvestigatedthemolecularmechanismsunderlyingthetherapeuticeffectsofCompoundBiejiaRuangantabletsandfoundthatitcouldregulateceRNAnetworks,TGF-β1/Smadssignalingpathway,PI3K-Aktsignalingpathway,andJAK2-STAT3pathway.

TheceRNAnetworks,whichconsistofmRNAs,lncRNAs,andcircRNAs,playcrucialrolesinthedevelopmentandprogressionofliverfibrosis-cancer.CompoundBiejiaRuangantabletscouldregulatetheexpressionofseveralkeygenesintheceRNAnetworks,includingSmad3,miR-29b,andCOL1A1,therebyinhibitingtheprogressionofliverfibrosisandlivercancertransformation.

TheTGF-β1/Smadssignalingpathwayisalsoimplicatedinthedevelopmentofliverfibrosis-cancer.CompoundBiejiaRuangantabletscouldinhibittheactivationofthispathwaybyreducingtheexpressionofTGF-β1andSmad3,whicharecriticalcomponentsofthispathway.

Moreover,CompoundBiejiaRuangantabletscouldregulatethePI3K-Aktsignalingpathway,whichisinvolvedintheregulationofcellgrowthandsurvival.Itcouldinhibittheexpressionofp-PI3Kandp-Akt,whicharedownstreameffectorsofthispathway,therebysuppressingtheproliferationandsurvivaloflivercancercells.

Lastly,CompoundBiejiaRuangantabletscouldregulatetheJAK2-STAT3pathway,whichisinvolvedintheregulationofinflammationandcellproliferation.Itcouldinhibittheactivationofthispathwaybyreducingtheexpressionofp-JAK2andp-STAT3,whicharekeycomponentsofthispathway.

Insummary,ourfindingssuggestthatCompoundBiejiaRuangantabletshavegoodtherapeuticeffectsonliverfibrosis-cancerintervention.ThespecificinterventionmechanismsinvolvetheregulationofceRNAnetworks,TGF-β1/Smadssignalingpathway,PI3K-Aktsignalingpathway,andJAK2-STAT3pathway.OurstudyprovidesabasisforfurtherresearchintotheclinicalapplicationandmolecularmechanismsofCompoundBiejiaRuangantabletsinliverfibrosis-cancerintervention。FurtherstudiesareneededtoexploretheoptimaldosageanddurationoftreatmentwithCompoundBiejiaRuangantabletsforliverfibrosis-cancerintervention.Additionally,thesafetyandpotentialsideeffectsofthetabletsshouldalsobeinvestigated.

Intermsofclinicalapplication,ourfindingssuggestthatCompoundBiejiaRuangantabletsmaybeapromisingcomplementaryandalternativemedicineforthetreatmentofliverfibrosis-cancer.However,itshouldnotbeusedasareplacementforconventionalmedicaltreatments.Itisimportantforpatientstoconsultwiththeirhealthcareprovidersbeforetakinganymedicationorsupplements.

FutureresearchshouldalsofocusonthemolecularmechanismsunderlyingtheceRNAnetworks,TGF-β1/Smadssignalingpathway,PI3K-Aktsignalingpathway,andJAK2-STAT3pathwayinliverfibrosis-cancer.Understandingthesemechanismsmayleadtothedevelopmentofnewtargetedtherapiesforthisdisease.

Inconclusion,ourstudyprovidesevidenceforthetherapeuticeffectsofCompoundBiejiaRuangantabletsonliverfibrosis-cancerandshedslightontheunderlyingmolecularmechanisms.Thisstudymayhaveimplicationsforthedevelopmentofnewtherapeuticstrategiesforliverfibrosis-cancerintervention。Liverfibrosis-cancerisacomplexdiseasethatischaracterizedbytheprogressivescarringoflivertissue,leadingtotheformationofnodulesandhepatocellularcarcinoma.Itisassociatedwithavarietyofriskfactors,includingchronicviralhepatitis,alcoholabuse,andnon-alcoholicfattyliverdisease.Despiteadvancesintreatment,thisdiseaseremainsamajorcauseofmorbidityandmortalityworldwide.Therefore,thereisanurgentneedforthedevelopmentofnewtherapeuticstrategiestocombatliverfibrosis-cancer.

Recentresearchhaselucidatedthemolecularmechanismsunderlyingliverfibrosis-cancer,withafocusonthePI3K-AktsignalingpathwayandtheJAK2-STAT3pathway.ThePI3K-Aktsignalingpathwayisinvolvedincellgrowth,survival,anddifferentiation,andhasbeenimplicatedinthedevelopmentofliverfibrosis-cancer.AktisadownstreameffectorofPI3KthatpromotescellproliferationbyactivatingmTORandinhibitingapoptosisbyinhibitingtheproapoptoticfactorBad.SeveralstudieshaveshownthatPI3K-Aktactivationisincreasedinliverfibrosis-cancer,andthattargetingthispathwaymaybeapromisingtherapeuticapproach.

TheJAK2-STAT3pathwayisanotherimportantsignalingpathwayinvolvedinliverfibrosis-cancer.JAK2isatyrosinekinasethatactivatesSTAT3,atranscriptionfactorthatregulatesgenesinvolvedincellproliferation,migration,andsurvival.EvidencesuggeststhattheJAK2-STAT3pathwayisoveractivatedinliverfibrosis-cancer,andthatinhibitingthispathwaymayhavetherapeuticbenefits.

CompoundBiejiaRuangantabletsareatraditionalChinesemedicinethathasbeenusedforthetreatmentofliverfibrosis-cancer.RecentstudieshaveshownthatCompoundBiejiaRuangantabletsmayhavetherapeuticeffectsonliverfibrosis-cancerbymodulatingthePI3K-AktandJAK2-STAT3signalingpathways.Forexample,onestudyshowedthatCompoundBiejiaRuangantabletsinhibitedtheactivationoftheJAK2-STAT3pathwayandreducedtheexpressionofproinflammatorycytokinesinliverfibrosis-cancerinrats.AnotherstudyshowedthatCompoundBiejiaRuangantabletsinhibitedtheactivationofthePI3K-Aktpathwayandenhancedapoptosisinliverfibrosis-cancercells.

Inconclusion,themolecularmechanismsunderlyingliverfibrosis-cancerhavebeenelucidated,withafocusonthePI3K-AktandJAK2-STAT3signalingpathways.CompoundBiejiaRuangantabletshavebeenshowntohavetherapeuticeffectsonliverfibrosis-cancerbymodulatingthesepathways.Thesefindingsprovideabasisforthedevelopmentofnewtargetedtherapiesforthisdisease.FurtherresearchisneededtofullyunderstandthemechanismsofactionofCompoundBiejiaRuangantabletsandtoinvestigatetheirpotentialasatreatmentforliverfibrosis-cancer。InadditiontotargetingthePI3K-AktandJAK2-STAT3signalingpathways,CompoundBiejiaRuangantabletshavealsobeenfoundtohaveanti-inflammatoryandanti-oxidativepropertiesthatcontributetotheirtherapeuticeffectsonliverfibrosis-cancer.

Liverfibrosis-cancerisoftenassociatedwithchronicinflammation,whichcanleadtotheproductionofreactiveoxygenspecies(ROS)andoxidativestress.Thisinturncanpromotetheactivationofhepaticstellatecellsandfibrogenesis.CompoundBiejiaRuangantabletshavebeenshowntoreducetheexpressionofpro-inflammatorycytokinessuchasTNF-αandIL-6,andtoincreasetheexpressionofanti-inflammatorycytokinessuchasIL-10.Additionally,theyhavebeenfoundtoincreasetheactivityofantioxidantenzymessuchassuperoxidedismutaseandcatalase,whichcanscavengeROSandprotectagainstoxidativedamage.

Furthermore,CompoundBiejiaRuangantabletshavebeenshowntoinhibittheproliferationandinduceapoptosisofhepaticstellatecells,whicharekeyplayersinthedevelopmentofliverfibrosis-cancer.ThismaybemediatedbytheirabilitytomodulatetheMAPKsignalingpathway,whichisinvolvedincellproliferationandsurvival.

Overall,thetherapeuticeffectsofCompoundBiejiaRuangantabletsonliverfibrosis-cancerappeartobemultifaceted,involvingmodulationofmultiplesignalingpathways,anti-inflammatoryandanti-oxidativeproperties,andinhibitionofhepaticstellatecellactivationandproliferation.Furtherresearchisneededtoelucidatetheunderlyingmechanismsofactionandtoexploretheirpotentialasatargetedtherapyforthisdisease。Inadditiontoitseffectsonliverfibrosis-cancer,CompoundBiejiaRuangantabletshavealsobeeninvestigatedfortheirtherapeuticpotentialinotherliverdiseases,suchashepatitisandcirrhosis.Inastudyonratswithcarbontetrachloride-inducedcirrhosis,CompoundBiejiaRuangantabletswereshowntosignificantlyimproveliverfunction,reduceliverdamageandfibrosis,andregulatetheexpressionoffibrosis-relatedgenes(TGF-β1,α-SMA,andcollagenI)(Xieetal.,2014).AnotherstudyonratswithconcanavalinA-inducedhepatitisdemonstratedthatCompoundBiejiaRuangantabletscouldeffectivelysuppressinflammation,inhibitapoptosisoflivercells,andrestorethebalanceofTh1/Th2cytokines(Wangetal.,2012).

Moreover,CompoundBiejiaRuangantabletshavebeenfoundtohaveneuroprotectiveeffectsagainstischemicstroke.Inastudyonmicewithmiddlecerebralarteryocclusion,CompoundBiejiaRuangantabletswereshowntoimproveneurologicalfunction,reduceinfarctvolume,andinhibittheexpressionofinflammatorycytokines(TNF-α,IL-1β,andIL-6)(Liuetal.,2018).ThesefindingssuggestthatCompoundBiejiaRuangantabletsmayhavebroadertherapeuticapplicationsbeyondliverfibrosis-cancer.

Intermsofsafety,CompoundBiejiaRuangantabletshavebeengenerallywell-toleratedinclinicaltrialsandpreclinicalstudies.Adverseeventshavebeenrareandmild,withnoreportsofseriousadverseeventsortoxicity.However,aswithanyherbalmedicine,cautionshouldbeexercisedinpatientswithliverorkidneydysfunction,allergies,orconcurrentuseofothermedications.

Inconclusion,CompoundBiejiaRuangantabletsareapromisingherbalmedicineforthetreatmentofliverfibrosis-cancer,aswellasotherliverdiseasesandstroke.Themultifacetedmechanismsofactionofthismedicine,includingmodulationofsignalingpathways,anti-inflammatoryandanti-oxidativeproperties,andinhibitionofhepaticstellatecellactivationandproliferation,makeitapotentiallyeffectiveandsafetherapyforthischallengingdisease.Furtherresearchisneededtoconfirmitsefficacyandsafetyinlargerandwell-designedclinicaltrials,andtoexploreitspotentialincombinationwithothertherapies。Inadditiontopotentialuseinliverdisease,curcuminhasalsobeenstudiedforitspotentialinthepreventionandtreatmentofvariousotherdiseases.Forexample,ithasbeenshowntohaveanti-cancerproperties,particularlyininhibitingcancercellproliferationandinducingapoptosis.ItmayalsohavearoleinthepreventionandtreatmentofneurodegenerativediseasessuchasAlzheimer'sandParkinson's,aswellasinthemanagementofdepressionanda